Murph
:)
- Messages
- 1,799
Maybe a drug company that has got a drug through a Phase 1 safety trial is now being trialled in other conditions? The odds of it working for me/cfs are probably slim so I think the hype is unjustified, but still, there is some modest reason for hope.
Perhaps it failed its phase ii efficacy trial on the intended target and now they are branching out to see if they can recoup some money by seeing if it works in other, related conditions. Rather than being annoyed at the small sample size, I'd say that's a good feature of an early phase trial on humans. If I was an ethics committee, I'd approve only a small trial to start.
The PR blitz is weird, but the inclusion of Jarred Younger makes me moderately more confident. It does seem quite possible the company is trying to go public to raise capital to keep going. They may have a safe, innovative, peptide that narrowly missed its primary endpoints in another trial and they now need $$ to not go bankrupt.. That's just business, - it doesn't prove the drug won't be helpful in other conditions!
EDIT 2: here's some more detail on the corporate structures: Seems the drug is IP that was sold off from a big company to a start up. "Hi Anne, the company is a start up pharmaceutical company, so there is no stock symbol. The drug was developed by a $700m company that was owned by a much larger company. We have articles coming out soon on the story, so stay tuned."
The big news here maybe is that a start-up recognises that there may be a market for a CFS cure! That's a great sign.
EDIT 1: making me lose a bit of confidence is this claim by Rich Carson in the facebook feed that they've developed an 'animal model of cfs':
"Exposing the rats to tremendous stress. They never recovered. Developed symptoms similar to those in ME--lower body temp, increased heart rate, decreased blood pressure, decreased movement--and they did not recover, until the drug was administered."
Perhaps it failed its phase ii efficacy trial on the intended target and now they are branching out to see if they can recoup some money by seeing if it works in other, related conditions. Rather than being annoyed at the small sample size, I'd say that's a good feature of an early phase trial on humans. If I was an ethics committee, I'd approve only a small trial to start.
The PR blitz is weird, but the inclusion of Jarred Younger makes me moderately more confident. It does seem quite possible the company is trying to go public to raise capital to keep going. They may have a safe, innovative, peptide that narrowly missed its primary endpoints in another trial and they now need $$ to not go bankrupt.. That's just business, - it doesn't prove the drug won't be helpful in other conditions!
EDIT 2: here's some more detail on the corporate structures: Seems the drug is IP that was sold off from a big company to a start up. "Hi Anne, the company is a start up pharmaceutical company, so there is no stock symbol. The drug was developed by a $700m company that was owned by a much larger company. We have articles coming out soon on the story, so stay tuned."
The big news here maybe is that a start-up recognises that there may be a market for a CFS cure! That's a great sign.
EDIT 1: making me lose a bit of confidence is this claim by Rich Carson in the facebook feed that they've developed an 'animal model of cfs':
"Exposing the rats to tremendous stress. They never recovered. Developed symptoms similar to those in ME--lower body temp, increased heart rate, decreased blood pressure, decreased movement--and they did not recover, until the drug was administered."
Last edited: